China Meningococcal Vaccines Market Size & Outlook

The meningococcal vaccines market in China is expected to reach a projected revenue of US$ 256.5 million by 2033. A compound annual growth rate of 8.6% is expected of China meningococcal vaccines market from 2026 to 2033.
Revenue, 2025 (US$M)
$126.0
Forecast, 2033 (US$M)
$256.5
CAGR, 2026 - 2033
8.6%
Report Coverage
China

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

China meningococcal vaccines market, 2021-2033 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

China meningococcal vaccines market highlights

  • The China meningococcal vaccines market generated a revenue of USD 126.0 million in 2025 and is expected to reach USD 256.5 million by 2033.
  • The China market is expected to grow at a CAGR of 8.6% from 2026 to 2033.
  • In terms of segment, menveo was the largest revenue generating brand in 2025.
  • Nimenrix is the most lucrative brand segment registering the fastest growth during the forecast period.


Meningococcal vaccines market data book summary

Market revenue in 2025USD 126.0 million
Market revenue in 2033USD 256.5 million
Growth rate8.6% (CAGR from 2026 to 2033)
Largest segmentMenveo
Fastest growing segmentNimenrix
Historical data2021 - 2024
Base year2025
Forecast period2026 - 2033
Quantitative unitsRevenue in USD million
Market segmentationMenactra, Menveo, Nimenrix, Trumenba, Bexsero
Key market players worldwidePfizer Inc, Sanofi SA, GSK PLC, Merck & Co Inc, Serum Institute of India Pvt. Ltd., Walvax Biotechnology


Other key industry trends

  • In terms of revenue, China accounted for 3.1% of the global meningococcal vaccines market in 2025.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
  • In Asia Pacific, China meningococcal vaccines market is projected to lead the regional market in terms of revenue in 2033.
  • Thailand is the fastest growing regional market in Asia Pacific and is projected to reach USD 52.7 million by 2033.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Meningococcal Vaccines Market Companies

Name Profile # Employees HQ Website
Walvax Biotechnology View profile 11-50 Kunming, Yunnan, China, Asia http://www.walvax.com
Serum Institute of India Pvt. Ltd. View profile 1001-5000 Pune, Maharashtra, India, Asia http://www.seruminstitute.com/
GSK PLC View profile 70200 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS https://www.gsk.com
Merck & Co Inc View profile 72000 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 https://www.merck.com
Sanofi SA View profile 87994 46, avenue de la Grande Armée, Paris, France, 75017 https://www.sanofi.com
Pfizer Inc View profile 88000 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 https://www.pfizer.com

China meningococcal vaccines market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to meningococcal vaccines market will help companies and investors design strategic landscapes.


Menveo was the largest segment with a revenue share of 34.05% in 2025. Horizon Databook has segmented the China meningococcal vaccines market based on menactra, menveo, nimenrix, trumenba, bexsero covering the revenue growth of each sub-segment from 2021 to 2033.


For instance, in February 2018, International group of expert doctors, scientists, and health officials reported in the Journal of Infection that effective MenB vaccination strategy was needed to combat the increasing cases of MenB since 2011.

For instance, in January 2022, CanSinoBIO received marketing approval from the National Medical Products Administration of China (NMPA) for its ACYW135 Meningococcal Conjugate Vaccine, Menhycia in the country.

Priority Review Designation for pipeline vaccines is expected to accelerate approvals in the country. Moreover, inclusion of meningococcal vaccination in National Immunization Program is also fueling market growth. MenA and MenAC polysaccharide/conjugate vaccines are incorporated into the NIP for children in the country.

Reasons to subscribe to China meningococcal vaccines market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of China meningococcal vaccines market databook

  • Our clientele includes a mix of meningococcal vaccines market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the China meningococcal vaccines market , including forecasts for subscribers. This country databook contains high-level insights into China meningococcal vaccines market from 2021 to 2033, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

China Brand - Meningococcal Vaccines Market size, 2025 - 2033 (US$M)

China Meningococcal Vaccines Market Outlook Share, 2025 & 2033 (US$M)

China Brand - Meningococcal Vaccines Market size, 2025 - 2033 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online